INDIANAPOLIS, Sept. 13, 2010 (GLOBE NEWSWIRE) -- Positron Corporation (OTCBB:POSC), a molecular imaging company specializing in Nuclear Cardiology and a leader in Cardiac PET, announced today the grand opening of its Clinical and Technical Cardiovascular PET Training Institute in Niagara Falls, NY.
The training center will educate physicians, technologists, nurses and administrators on the use and benefits of cardiac PET imaging in the daily operations of their facility. The training will be done in a partnership with the Heart Center of Niagara where Positron's medical director, Michael E. Merhige, M.D., F.A.C.C currently operates a Coronary Artery Disease Reversal and Prevention Center guided by Positron PET imaging technologies.
Positron's chief technical officer, Joe Oliverio, stated, "This center will be a critical tool in building awareness of the tangible benefits a dedicated cardiac PET scanner yields. Creating a center specifically geared towards disseminating information is critically important as we work to grow the adaptation of PET scanners into the medical imaging marketplace. As an early adaptor of cardiac PET imaging, Dr. Merhige is an ideal ambassador to the medical community; tapping into the combined decades of experience Dr. Merhige and Positron's clinical staff possess, will allow a seamless transition of users from SPECT to PET."
Dr. Michael E. Merhige said, "Cardiac PET has been around since 1995, but only until very recently has the necessary peer-reviewed literature been available to allow for its proper recognition. PET scanning for cardiac use exposes the patient to significantly reduced levels of radiation, compared to SPECT, while affording physicians a highly effective diagnostic tool. I am pleased to play a role in educating my peers on the benefits of a cardiac PET scanner."
About Positron: Positron is a molecular imaging company focused on Nuclear Cardiology. Positron utilizes its proprietary product line to provide unique solutions to the Nuclear Medicine community ranging from imaging to radiopharmaceutical distribution. Positron products include: the Attrius™, a PET imaging device; the Pulse®, a SPECT imaging device; the Nuclear Pharm-Assist®, an automated radiopharmaceutical distribution device; and the Tech-Assist™, a radiopharmaceutical injection shield. More information about Positron is available at www.positron.com.
Forward Looking Statements: Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance and may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Positron Corporation to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Positron assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as "Risk Factors" in our filings with the Securities and Exchange Commission.